共 81 条
[1]
Bai X(2021)Risk models for advanced melanoma patients under anti-PD-1 monotherapy-ad hoc analyses of pooled data from two clinical trials Front Oncol 11 639085-247
[2]
Dai J(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 1 228-409
[3]
Li C(2018)Reference values for white blood-cell-based inflammatory markers in the Rotterdam study: a population-based prospective cohort study Sci Rep 8 10566-536
[4]
Eisenhauer EA(2020)The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials Br J Cancer 123 403-317
[5]
Therasse P(2021)The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy Target Oncol 16 529-681
[6]
Bogaerts J(2021)Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients Clin Transl Oncol 23 311-921
[7]
Fest J(2016)Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma J Dtsch Dermatol Ges 14 662-35299
[8]
Ruiter R(2018)Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV mela-noma J Surg Oncol 118 915-3040
[9]
Ikram MA(2018)Systemic immune-inflammation index, SII, for prognosis of elderly patients with newly diagnosed tumors Oncotarget 9 35293-353
[10]
Voortman T(2015)Inflammation fuels tumor progress and metastasis Curr Pharm Des 21 3032-12470